Investors have piled into bets against Novavax, the struggling vaccine developer that was late to market with its Covid-19 vaccine. Roughly 50% of outstanding Novavax shares are currently sold short, making it the most bet-against stock in the U.S., according to S&P Global Market Intelligence data.
